出版專著： 
[1]、《新藥非臨床研究與開發(fā)》 ，徐寒梅 主編，中國醫(yī)藥科技出版社，2020年7月。
[2]、《抗腫瘤藥物藥理學(xué)實驗指南》，主編：徐寒梅 ，副主編:李夢瑋，羅燕平，中國醫(yī)藥科技出版社，2015年10月。
[3]、《酶類藥物學(xué)》，主編 吳梧桐，執(zhí)行主編：袁勤生，副主編：徐寒梅，中國醫(yī)藥科技出版社，2011年1月
發(fā)表英文論文：.
1.Chaowei Hao, Peng Chen, Sarra Setrerrahmane, Hanmei Xu*, A Peptide-Salinomycin Conjugate with a Bystander Effect Reduces the Stemness Characteristics of Ovarian Cancer Cells and Enhances Drug Sensitivity, European Journal of Medicinal Chemistry, 2024, 276, 116701. https://doi.org/10.1016/j.ejmech.2024.116701. (IF=6)
2.Xiaowei Xu , Jian Li c , Sarra Setrerrahmane d , Juan Zhang e , Suoqin Shi b , Yahui Hu b , Dong Lin b , Hanmei Xu*, A multifunctional antibody fusion protein 57103 targeting CD24, IL-4R, and αvβ3 for treating cancer and regulating the tumor microenvironment,Biomedicine & Pharmacotherapy,2024 Jun:175:116714.doi:10.1016/j.biopha.2024.116714.(IF:7.419)
3.Jiaqi Wang1, Dong Wang1,Sarra Setrerrahmane3,Jean Martinez, Han-Mei Xu*，The peptide Acein promotes dopamine secretion through clec-126 to extend elderly C. elegans lifespan ，AGING-US，2023 Dec 27:15.doi: 10.18632/aging.205150.（IF=5.2）
4.Peiwei Yang，F(xiàn)an Yu， Zheng Yao， Xu Ding， Hanmei Xu*，Juan Zhang*.CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer,Cancer Immunology Immunotherapy ,2023 Oct;72(10):3191-3202. doi: 10.1007/s00262-023-03491-7.（IF=5.8）
5.Mengwei Li#, Guangxiang Liu#, Xinrong Jin, Hongqian Guo, Sarra Setrerrahmane, Xindi Xu, Tiantian Li, Yunfei Lin, Hanmei Xu*, Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma, Mol Cancer. Mol Cancer 21, 181 (2022). doi: 10.1186/s12943-022-01654-1. (IF= 37.3)
6.Li, Mengwei; Chi, Xiaowei; Wang, Ying; Setrerrahmane, Sarra; Xie, Wenwei; Xu, Hanmei*，Trends in insulin resistance: insights into mechanisms and therapeutic strategy，Signal transduction and targeted therapy，2022 Jul 6;7(1):216. doi: 10.1038/s41392-022-01073-0.（IF=40.8）
7.Setrerrahmane, Sarra; Li, Mengwei; Zoghbi, Abdelmoumin; Lv, Xue; Zhang, Sen; Zhao, Wenjing; Lu, Jingjing; Craik, David J; Xu, Hanmei*，Cancer-related micropeptides encoded by ncRNAs: Promising drug targets and prognostic biomarkers，Cancer letters，547：215723. DOI: 10.1016/j.canlet.2022.215723（IF=9.7）
8.Shi, GB;Kang, XY;Dong, FY;Liu, YC;Zhu, N;Hu, YX;Xu, HM*;Lao, XZ;Zheng, H;DRAMP 3.0: an enhanced comprehensive data repository of antimicrobial peptides;NUCLEIC ACIDS RESEARCH; 2022 Jan 7;50(D1):D488-D496. doi: 10.1093/nar/gkab651（IF=14.9）
9.Bai, ZK;Yang, PW;Yu, F;Li, Z;Yao, Z;Martinez, J;Li, MW;Xu, HM*；Combining adoptive NK cell infusion with a dopamine-releasing peptide reduces senescent cells in aged mice；CELL DEATH & DISEASE；2022 Apr 5;13(4):305.doi: 10.1038/s41419-022-04562-w.（IF=9.0）
10.Ji, W;Lu, YY;Ma, ZY;Gan, K;Liu, Y;Cheng, Y;Xu, JL;Liu, SJ;Guo, YK;Han, SH;Zhao, ZY;Xu, HM;Qi, WY. Triptolide attenuates inhibition of ankylosing spondylitis-derived mesenchymal stem cells on the osteoclastogenesis through modulating exosomal transfer of circ-0110634[J]. Journal of Orthopaedic Translation, 2022, 36: 132-144. DOI: 10.1016/j.jot.2022.05.007. (IF=6.6)
11.Wang Y, Li M, Chen L, Bian H, Chen X, Zheng H, Yang P, Chen Q, Xu H*. Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes. Signal Transduction and Targeted Therapy. 2021;6(1):409. DOI: 10.1038/s41392-021-00805-y. (IF=39.3)
12.Xingran Du #, Jianpeng Xue #, Mingzi Jiang, Shaoqing Lin, Yuzhen Huang, Kaili Deng, Lei Shu, Hanmei Xu*, Zeqing Li, Jing Yao, Sixia Chen, Ziyan Shen, Ganzhu Feng. A Multiepitope Peptide, rOmp22, Encapsulated in Chitosan-PLGA Nanoparticles as a Candidate Vaccine Against Acinetobacter baumannii Infection. Int J Nanomedicine. 2021;16:1819-1836. Published 2021 Mar 4. doi:10.2147/IJN.S296527 (IF=8.0)
13.Wen Huang, Yaqi Lan, Wanwen Liao, Li Lin, Guo Liu, Hanmei Xu*, Jianpeng Xue, Baoyan Guo, Yong Cao, Jianyin Miao, Preparation, characterization and biological activities of egg white peptides-calcium chelate, LWT, Volume 149, 2021.DOI: 10.1016/j.lwt.2021.112035 (IF= 6.056)
14.Meng Li, Ying Wang, Mengwei Li, Xuezhen Wu, Sarra Setrerrahmane, Hanmei Xu*, Integrins as attractive targets for cancer therapeutics, Acta Pharmaceutica Sinica B, 2021;11(9):2726-2737. DOI: 10.1016/j.apsb.2021.01.004 (IF=14.5)
15.Meng Li, Hanmei Xu*, Junzhi Wang, Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment, Acta Pharmaceutica Sinica B, 2020, 10(2):262-275 .DOI: 10.1016/j.apsb.2019.10.010 (IF=14.5)
16.Peiwei Yang, Ying Wang, Zheng Yao, Xinmei Gao, Chen Liu, Xinmin Wang, Heming Wu, Xu Ding, Jialiang Hu, Bingjing Lin, Qian Li, Mengwei Li, Xin Li, Xiangying Chen, Weiyan Qi, Weiguang Li, Jianpeng Xue,* and Hanmei Xu*. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. J Am Chem Soc. 2020 Nov 4;142(44):18874-18885. doi: 10.1021/jacs.0c08538. Epub 2020 Oct 2. (IF=15.0)
17.Mengwei Li, Xu Ding, Yinan Zhang, Xin Li, Haoze Zhou, Li Yang, Yilin Li, Peiwei Yang, Xiaomin Zhang, Jialiang Hu, Edouard Nice, Heming Wu, Hanmei Xu*. Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas. Cell Death Dis. 2020 Aug 13;11(8):672. doi: 10.1038/s41419-020-02820-3. (IF=9.0)
18.Mengwei Li, Xin Li, Yinan Zhang, Heming Wu, Haoze Zhou, Xu Ding, Xiaomin Zhang, Xinrong Jin, Ying Wang, Xinqiang Yin, Chencheng Li, Peiwei Yang, Hanmei Xu*. Micropeptide MIAC Inhibits HNSCC Progression by Interacting with Aquaporin 2. J Am Chem Soc. 2020 Apr 8;142(14):6708-6716. doi: 10.1021/jacs.0c00706. (IF=15.0)
19.Ying Wang, Jiqiang Lu, Lin Chen, Huan Bian, Jialiang Hu, Dongping Li, Chunlei Xia, Hanmei Xu*. Tumor-Derived EV-Encapsulated miR-181b-5p Induces Angiogenesis to Foster Tumorigenesis and Metastasis of ESCC. Mol Ther Nucleic Acids. 2020 Jun 5;20:421-437. doi: 10.1016/j.omtn.2020.03.002. (IF=8.8)
20.Ying Wang, Dongping Li, Jiqiang Lu, Lin Chen, Shengnan Zhang, Weiyan Qi, Weiguang Li, Hanmei Xu*. Long noncoding RNA TTN-AS1 facilitates tumorigenesis and metastasis by maintaining TTN expression in skin cutaneous melanoma. Cell Death Dis. 2020 Aug 20;11(8):664. doi: 10.1038/s41419-020-02895-y. (IF=9.0)
21.Li Dongping, Wang Ying, Jin Xinrong, Hu Die, Xia Chunlei, Xu Hanmei*, Hu Jialiang*. NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice.[J]. J Neuroinflammation, 2020, Apr 22, 17: 126 sci：5.7. DOI: 10.1186/s12974-020-01787-4（IF=9.3）
22.Qi Weiyan, Gao Xinmei, Ma Zhuoyi, Xia Chunlei, Xu Hanmei *. Antiangiogenic Activity of Terpenoids From Euphorbia Neriifolia Linn[J]. Bioorganic Chemistry, 2020, Mar, 96: 103536. sci:3.8 doi: 10.1016/j.bioorg.2019.103536（IF=5.1）
23.Xinqiang Yin, Yuanyuan Jing, Quan Chen, Abdul Baset Abbas, Jialiang Hu, Hanmei Xu*. The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test. European Journal of Pharmacology, 870 (2020) 172909. Sci: 3.17 doi: 10.1016/j.ejphar.2020.172909（IF=5.0）
24.Abbas AB, Lin B, Liu C, Morshed A, Hu J*, Xu H*. Design and synthesis of a PD-1 binding peptide and its anti-tumor activity evaluation. Int J Mol Sci. 2019 Jan 29;20(3). pii: E572.DOI: 10.3390/ijms20030572 (IF=5.6)
25.Weiguang Li, Jianpeng Xue, Hanmei Xu*. Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy. International Journal of Nanomedicine, 2019,14 : 1011—1026.DOI: 10.2147/ijn.s189864 (IF=8.0)
26.Xinqiang Yin, Jialiang Hu, Hanmei Xu*, Distribution of micropeptide-coding sORFs in transcripts, Chinese Chemical Letters, 2018, 29(7):1029-1032. DOI: 10.1016/j.cclet.2018.04.027 (IF:8.455)
27.Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi, Sun Q, Zhang S, Hu J, Xu H*. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018, 11(1):102 DOI: 10.1186/s13045-018-0646-9 (IF= 28.5)
28.Huang R, Li J, Wang Y, Zhang L, Ma X, Wang H, Li W, Cao X, Xu H*, Hu J. The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis. Int J Mol Sci. 2018 Sep 10;19(9). pii: E2683. DOI: 10.3390/ijms19092683 (IF= 5.6)
29.Erhao Zhang, Jieyi Gu and Hanmei Xu*. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018, 17(1):7. DOI: 10.1186/s12943-018-0759-3 (IF= 37.3)
30.Lin C, Zhang S, Wang Y, Wang Y, Nice E, Guo C, Zhang E, Yu L, Li M, Liu C, Hu L, Hao J, Qi W, Xu H*. Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis. Clin Cancer Res. 2018, 24(2):486-498. DOI: 10.1158/1078-0432.ccr-17-1851 (IF= 11.5)
31.Zhang E, Gu J, Xue J, Lin C, Liu C, Li M, Hao J, Setrerrahmane S, Chi X, Qi W, Hu J*, Xu H*. Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide. J Hematol Oncol. 2018 Mar 20;11(1):44. doi: 10.1186/s13045-018-0591-7. (IF= 28.5)
32.Li M, Han Y, Zhou H, Li X, Lin C, Zhang E, Chi X, Hu J, Xu H*. Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/β-catenin pathway. Cell Death Dis. 2018 Jan 24;9(2):91. DOI: 10.1038/s41419-017-0128-y (IF= 9.0)
33.Setrerrahmane S, Xu H*. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017 Sep 19;16(1):153. doi: 10.1186/s12943-017-0721-9. (IF= 37.3)
34.Hao J, Wu X, Setrerrahmane S, Qian K, Hou Y, Yu L, Lin C, Wu Q, Xu H*. Combination Therapy of PEG-HM-3 and Methotrexate Retards Adjuvant-Induced Arthritis. Int J Mol Sci. 2017 Jul 21;18(7). pii: E1538. doi: 10.3390/ijms18071538. (IF= 5.6)
35.Erhao Zhang, Hanmei Xu*. A new insight in chimeric antigen reeptor-engineered T cells for cancer immunotherapy. Journal of Hematology and Oncology, 2017,10:1-11.DOI: 10.1186/s13045-016-0379-6（IF= 28.5）
36.C Lin, Y Wang, Y Wang, S Zhang, L Yu, C Guo and H Xu*. Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells. Oncogene (2017), 36(38):5392-5406.DOI: 10.1038/onc.2017.133 （IF= 8.0）
37.C Zhao, J He, H Cheng, Z Zhu, H Xu*. Enhanced therapeutic effect of an antianiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct. Journal of Experimental & Clinical Cancer Research.2016, 35:107-117. DOI: 10.1186/s13046-016-0381-4 （IF=11.3）
38.Zheng Qiu, Fengguo Zhang, Chengxin Gong, Hanmei Xu*, Jialiang Hu*. Fusion peptides CPU1 and CPU2 inhibit matrix metalloproteinases and protect mice from endotoxin shock within a strict time window. Inflammation. 2015, 38(6):2092-2104.DOI: 10.1007/s10753-015-0192-3（IF=5.1）
39.X. Xu, S. Ren, X. Chen, J. Ge, Z. Xu, H. Huang, H. Sun, Y. Gu, T. Zhou, J. Li*, H. Xu*. Generation of hepatitis B virus preS2-S antigen in Hansenula polymorpha. Virologica Sinica, 2014, 29(6):4003-4009.DOI: 10.1007/s12250-014-3508-9 （IF=5.5）
40.Shen Hong, Han Haibing, Hu Jialiang, Zhang Xiaojuan, Wang jingjing, Wang Wenjing, Nie Caihui, Xu Hanmei*. PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation. Journal of Material Chemistry B, 2014, 2:800-813.DOI: 10.1039/c3tb21100b（IF=7.0）
41.Li Pan, Jialiang Hu, Wenjing Wang, Xiaojuan Zhang, Jin Wei, Zhendong Liu, Yihua Zhang* and Hanmei Xu*. Molecular Mechanisms of (R,R) ZX-5 on NO Synthesis and Its Anti-Angiogenic Effect. International Journal of Molecular Sciences, 2012, 13:2717-2726. DOI: 10.3390/ijms13032717（IF=5.6）
42.Zhendong Liu, Yinling Ren, Li Pan and Han-Mei Xu*, In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG). International Journal of Molecular Sciences, 2011, 12(4):2650-2663. DOI: 10.3390/ijms12042650（IF=5.6）
43.Guoqiu Wu, Xuepeng Deng , Hanmei Xu*. Application of immobilized thrombin for production of S-thanatin expressed in Escherichia coli. Applied Microbiology Biotechnology, 2011, 92(1):85-93. DOI: 10.1007/s00253-011-3379-z（IF=5.0）
44.Han-Mei Xu*, Jin Wei, Zilong Shen1*. The Mechanism of (R, R) ZX-5 Promoting Choroidal Blood Flow and Increasing NO Release. International Journal Molecular Sciences, 2010, 11(9):3323-3333.DOI: 10.3390/ijms11093323（IF=5.6）
點擊圖片查看原圖
